Cell No. : Cell Name
RCB1641 : EL4
update : 2022/04/06
|
| Comment | 9,10-dimethyl-1,2benzanthracene induced lymphoma. Since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECA 85023105 prior to order. |
| Comment from the depositor | |
| Terms and conditions | 1) There is no restriction regarding use for basic researches. However, since “Terms and conditions” etc. for this cell line can be changed, the users of this cell line must refer to ECA85023105 prior to order. 2) In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
ECACC
|
| Year of deposit |
2000
|
| Animal |
mouse
< Mammals
|
| Tissue |
ascites
|
| Disease name |
ascites lymphoma lymphoblast
|
| Metastastatic ability |
Yes
|
| Classification |
cancer
|
| History |
overseas, ECACC -> RIKEN Cell Bank
|
|
Lifespan |
infinite
|
| Morphology |
lymphoblast-like
|
| Cellosaurus(Expasy) |
CVCL_0255
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Suspension cells
|
| Medium and additives |
|
DMEM (low glucose) + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
pipetting
|
Culture information
|
Passage ratio |
|
1 : 10 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| SSLP(mouse) |
|
OK
|
| Isozyme |
|
LD, NP, PepB
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
6
|
| User's Publication |
7
|
| Reference |
|
716
Ralph P, Nakoinz I
Antibody-dependent killing of erythrocyte and tumor targets by macrophage-related cell lines: enhancement by PPD and LPS.
J Immunol
1977
119:950-54
PubMed ID: 894031
|
|
1141
Ralph P, Moore, M A, Nilsson K
Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines.
J Exp Med
1976
143:1528-33
PubMed ID: 1083890
DOI: 10.1084/jem.143.6.1528
|
|
2468
Herberman RB
Serological analysis of cell surface antigens of tumors induced by murine leukemia virus.
J Natl Cancer Inst
1972
48:265-71
PubMed ID: 4119883
|
|
2471
Shevach, E M, Stobo, J D, Green I
Immunoglobulin and theta-bearing murine leukemias and lymphomas.
J Immunol
1972
108:1146-51
PubMed ID: 4112916
|
|
2470
Old, L J, Boyse, E A, Stockert E
The G (Gross) leukemia antigen.
Cancer Res
1965
25:813-9
PubMed ID: 4284252
|
|
2469
Studies in antibody response of mice to tumour inoculation.
Br J Cancer
1950
4:372
PubMed ID: 14801344
DOI: 10.1038/bjc.1950.36
|
| User's Publication |
|
16857
Naruse C, Sugihara K, Miyazaki T, Pan X, Sugiyama F, Asano M.
A degron system targeting endogenous PD-1 inhibits the growth of tumor cells in mice
NAR Cancer
2022
4(2):zcac019
PubMed ID: 35734392
DOI: 10.1093/narcan/zcac019
|
|
20272
Ma Y, Yoshida T, Matoba K, Kida K, Shintani R, Piao Y, Jin J, Nishino T, Hanayama R.
Identification of small compounds regulating the secretion of extracellular vesicles via a TIM4-affinity ELISA.
Sci Rep
2021
11(1):13471
PubMed ID: 34188113
DOI: 10.1038/s41598-021-92860-2
|
|
4184
Kimura Y, Negishi H, Matsuda A, Endo N, Hangai S, Inoue A, Nishio J, Taniguchi T, Yanai H.
Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways.
Cancer Sci.
2018
PubMed ID: 29981256
DOI: 10.1111/cas.13726
|
|
14623
De Silva NH, Akazawa T, Wijewardana V, Inoue N, Oyamada M, Ohta A, Tachibana Y, Wijesekera DPH, Kuwamura M, Nishizawa Y, Itoh K, Izawa T, Hatoya S, Hasegawa T, Yamate J, Inaba T, Sugiura K.
Development of effective tumor immunotherapy using a novel dendritic cell-targeting Toll-like receptor ligand
PLoS One
2017
12(11):e0188738
PubMed ID: 29190690
DOI: 10.1371/journal.pone.0188738
|
|
14127
Kanda M, Yamanaka H, Kojo S, Usui Y, Honda H, Sotomaru Y, Harada M, Taniguchi M, Suzuki N, Atsumi T, Wada H, Baghdadi M, Seino K.
Transcriptional regulator Bhlhe40 works as a cofactor of T-bet in the regulation of IFN-γ production in iNKT cells
Proc Natl Acad Sci U S A
2016
113(24):E3394-402
PubMed ID: 27226296
DOI: 10.1073/pnas.1604178113
|
|
6489
Ando T, Ichikawa J, Wako M, Hatsushika K, Watanabe Y, Sakuma M, Tasaka K, Ogawa H, Hamada Y, Yagita H, Nakao A.
TWEAK/Fn14 interaction regulates RANTES production, BMP-2-induced differentiation, and RANKL expression in mouse osteoblastic MC3T3-E1 cells.
Arthritis Res Ther
2006
8(5):R146
PubMed ID: 16945157
DOI: 10.1186/ar2038
|
|
6976
Nagai N, Anzawa T, Satoh Y, Suzuki T, Tajima K, Munekata M.
Activities of MC3T3-E1 cells cultured on gamma-irradiated salmon atelocollagen scaffold.
J Biosci Bioeng
2006
101(6):511-4
PubMed ID: 16935254
DOI: 10.1263/jbb.101.511
|
Back
Top
CELL BANK Website
